Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 05, 2014 2:32pm
145 Views
Post# 22416077

RE:RE:Washington DC Mar 31

RE:RE:Washington DC Mar 31Hi G1945V.

All I did was go into my investment account (TSX listing) and then into RVX which then shows the trading status, trends and then it describes the # of shares in the float and outstanding shares. So that's the 51mm and 74mm respectively.

Then, based on memory from past posts, I guessed that Eastern + NgN + Don + Dr. Wong and family and friends and other executives might hold 53%...purely a guess!!! Perhaps it is much higher but what I remember from past postings is that these groups and people have voting control.

So then I applied 47% to the floating shares to get a crude idea of the possible maximum liquid shares. I realize that the 47% does include non liquid shareholders (like myself because I am not selling at least anywhere close to current prices).

Now I know from following the posts that a number of people, including you, have a much better grasp of the numbers than me so I defer to you and others who have done the analysis with more rigour than me.

What I'm trying to feel out is the approximate size of the liquid float. I'm looking for more rigorous analysis so please straighten me out. I do not want to lead anyone astray with grossly wrong numbers. 

So it's definitely DYODD on this one.

I think we all (???) recognize that at this stage the value in the short term will be driven by completion of the financing of the phase 2c trial and the form of the financing. This will give a significant vote of confidence to potential investors and the impact on whatever the size of the liquid float is.

As always, I'm here to learn.

Cheers
Toinv
Bullboard Posts